Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19


Mortality among tuberculosis patients under DOTS programme: a historical cohort study.

Beyene Y, Geresu B, Mulu A.

BMC Public Health. 2016 Aug 25;16:883. doi: 10.1186/s12889-016-3557-0.


Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial.

Polyak CS, Yuhas K, Singa B, Khaemba M, Walson J, Richardson BA, John-Stewart G.

PLoS Med. 2016 Jan 5;13(1):e1001934. doi: 10.1371/journal.pmed.1001934. eCollection 2016 Jan.


Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China.

Cheng W, Wu Y, Wen Y, Ma Y, Zhao D, Dou Z, Zhang W, Bulterys M, Zhang F.

Bull World Health Organ. 2015 Mar 1;93(3):152-60. doi: 10.2471/BLT.14.142745. Epub 2015 Jan 29.


Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review.

Saadani Hassani A, Marston BJ, Kaplan JE.

J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S257-69. doi: 10.1097/QAI.0000000000000486. Review. Erratum in: J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):e84.


Improved survival with co-trimoxazole prophylaxis among people living with HIV/AIDS who initiated antiretroviral treatment in Henan Province, China.

Zhu Q, Wang L, Lin W, Bulterys M, Yang W, Sun D, Cui Z, Kaplan J, Kleinman N, Wei X, Chung J, Wang Z.

Curr HIV Res. 2014;12(5):359-65.


Retrospective evaluation of cotrimoxazole use as preventive therapy in people living with HIV/AIDS in Boru Meda Hospital.

Geresu B, Misganaw D, Beyene Y.

BMC Pharmacol Toxicol. 2014 Feb 8;15:4. doi: 10.1186/2050-6511-15-4.


Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.

Hoffmann CJ, Chaisson RE, Martinson NA.

PLoS One. 2014 Jan 8;9(1):e83750. doi: 10.1371/journal.pone.0083750. eCollection 2014.


A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.

Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, Spyer MJ, Kekitiinwa A, Lutaakome J, Mhute T, Kasirye P, Munderi P, Musiime V, Gibb DM, Walker AS, Prendergast AJ; Antiretroviral Research for Watoto (ARROW) Trial Team.

N Engl J Med. 2014 Jan 2;370(1):41-53. doi: 10.1056/NEJMoa1214901. Erratum in: N Engl J Med. 2014 Jan 30;370(5):488. Dosage error in article text.


Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review.

Manyando C, Njunju EM, D'Alessandro U, Van Geertruyden JP.

PLoS One. 2013;8(2):e56916. doi: 10.1371/journal.pone.0056916. Epub 2013 Feb 22. Review.


The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa.

Kamya MR, Byakika-Kibwika P, Gasasira AF, Havlir D, Rosenthal PJ, Dorsey G, Achan J.

Future Virol. 2012;7(7):699-708.


National policy development for cotrimoxazole prophylaxis in Malawi, Uganda and Zambia: the relationship between Context, Evidence and Links.

Hutchinson E, Parkhurst J, Phiri S, Gibb DM, Chishinga N, Droti B, Hoskins S.

Health Res Policy Syst. 2011 Jun 16;9 Suppl 1:S6. doi: 10.1186/1478-4505-9-S1-S6.


Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review.

Sibanda EL, Weller IV, Hakim JG, Cowan FM.

Clin Infect Dis. 2011 May;52(9):1184-94. doi: 10.1093/cid/cir067. Review.


Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa.

Hoffmann CJ, Fielding KL, Charalambous S, Innes C, Chaisson RE, Grant AD, Churchyard GJ.

AIDS. 2010 Jul 17;24(11):1709-16. doi: 10.1097/QAD.0b013e32833ac6bc.


Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.

Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, Reid A, Katabira E, Grosskurth H, Mugyenyi P, Hakim J, Darbyshire JH, Gibb DM, Babiker AG.

Lancet. 2010 Apr 10;375(9722):1278-86. doi: 10.1016/S0140-6736(10)60057-8. Epub 2010 Mar 27.


Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Magaret AS, Wang RS, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C; Partners in Prevention HSV/HIV Transmission Study Team.

Lancet. 2010 Mar 6;375(9717):824-33. doi: 10.1016/S0140-6736(09)62038-9. Epub 2010 Feb 12.


CD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and Switzerland.

May M, Wood R, Myer L, Taffé P, Rauch A, Battegay M, Egger M; Cape Town AIDS Cohort; Swiss HIV Cohort Study.

J Infect Dis. 2009 Dec 1;200(11):1729-35. doi: 10.1086/648096.


Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.

Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, Flanigan TP, Lu Z, Weinstein MC, Wang B, Ganesh AK, Bender MA, Mayer KH, Walensky RP.

AIDS. 2007 Jul;21 Suppl 4:S117-28.


Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole.

Schaars CF, Meintjes GA, Morroni C, Post FA, Maartens G.

BMC Infect Dis. 2006 Jul 18;6:118.

Supplemental Content

Support Center